Abivax S.A.(ABVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVX Abivax S.A.

Market Closed 06-26 16:00:00 EDT

97.50

+5.13

+5.55%

盘后97.00

-0.50-0.51%

19:57 EDT

High99.23	Low93.02	Vol1.67M
Open93.02	D1 Closing92.37	Amplitude6.73%
Mkt Cap7.72B	Tradable Cap4.16B	Total Shares79.19M
T/O161.08M	T/O Rate3.91%	Tradable Shares42.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVX","market":"US","secType":"STK","nameCN":"Abivax S.A.","latestPrice":97.5,"timestamp":1782504000000,"preClose":92.37,"halted":0,"volume":1666908,"hourTrading":{"tag":"盘后","latestPrice":97,"preClose":97.5,"latestTime":"19:57 EDT","volume":5081,"amount":493719.517,"timestamp":1782518224362,"change":-0.5,"changeRate":-0.005128,"amplitude":0.014256},"delay":0,"changeRate":0.055537512179278936,"floatShares":42655700,"shares":79185160,"eps":-5.216782,"marketStatus":"Market Closed","change":5.13,"latestTime":"06-26 16:00:00 EDT","open":93.015,"high":99.2299,"low":93.015,"amount":161078520.79296002,"amplitude":0.067283,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.216782,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1697774400000,"exchange":"NASDAQ","adjPreClose":92.37,"preHourTrading":{"tag":"盘前","latestPrice":93.17,"preClose":92.37,"latestTime":"09:29 EDT","volume":17396,"amount":1605265.56558,"timestamp":1782480599999,"change":0.8,"changeRate":0.008661,"amplitude":0.041355},"postHourTrading":{"tag":"盘后","latestPrice":97,"preClose":97.5,"latestTime":"19:57 EDT","volume":5081,"amount":493719.517,"timestamp":1782518224362,"change":-0.5,"changeRate":-0.005128,"amplitude":0.014256},"volumeRatio":0.5952459258143983,"impliedVol":1.4845,"impliedVolPercentile":0.9223},"requestUrl":"/m/hq/s/ABVX/tweets","defaultTab":"tweets","newsList":[{"id":"2646366992","title":"European Equities Traded in the US as American Depositary Receipts Decline Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2646366992","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646366992?lang=en_us&edition=fundamental","pubTime":"2026-06-26 23:06","pubTimestamp":1782486382,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower Friday morning, decreasing 0.4% to 1,883.22 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech companies Evaxion  and Abivax , which gained 5.4% and 4.5% respectively. They were followed by healthcare firm Grifols  and drink and brewing giant Anheuser-Busch Inbev , which added 1.4% and 1.1%, respectively.The decliners from continental Europe were led by Agomab Therapeutics  and steel producer ArcelorMittal , which fell 3.9% and 3.5% respectively. They were followed by energy company Equinor , which was down 1.3%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways  and Autolus Therapeutics , which rose 5.6% and 2.8% respectively.The decliners from the UK and Ireland were led by semiconductor company Arm  and Barclays , which shed 4% and 1.3% respectively.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BUD","BK4585","BK4588","BK4521","ARMW","AGMB","IE00BMPRXN33.USD","LU0348723411.USD","BK4007","BK4006","BK4141","BK4201","ARM","ARMG","BK4543","BK4139","IE00BMPRXR70.SGD","ABVX","MT","GRFS","ARMU","CMPS","BK4609","EVAX","EQNR","BK4207","LU1232071149.USD","AUTL","LU2543165471.USD","ADRU","BK4561","IE00BMPRXQ63.HKD","LU0081259029.USD","BK4158","BCS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164658041","title":"Movement Alert｜Abivax S.A. Rises 5.48% in Regular Trading, Bull-Bear Debate Intensifies Amid Phase 3 Trial Safety Controversy","url":"https://stock-news.laohu8.com/highlight/detail?id=1164658041","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164658041?lang=en_us&edition=fundamental","pubTime":"2026-06-26 22:30","pubTimestamp":1782484216,"startTime":"0","endTime":"0","summary":"On June 26, Abivax S.A. rose 5.48% in regular trading, trading at $96.87/share, with turnover of $50.50 million.On the news front, the stock saw a notable intraday rebound as the bull-bear debate...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100699073","title":"Movement Alert｜Abivax S.A. Falls 5.38% in After-Hours Trading, Phase 3 Trial Safety Controversy Continues to Suppress Rebound Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1100699073","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100699073?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:05","pubTimestamp":1782417955,"startTime":"0","endTime":"0","summary":"On June 26, Abivax S.A. fell 5.38% in after-hours trading, trading at $92.37/share, with turnover of $247,000.On the news front, the ongoing safety controversy surrounding the company's core drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188776658","title":"Movement Alert｜Abivax S.A. Falls 5.62% in Regular Trading, Phase 3 Trial Safety Concerns Continue to Suppress Rebound Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1188776658","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188776658?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:34","pubTimestamp":1782405250,"startTime":"0","endTime":"0","summary":"On June 26, Abivax S.A. declined 5.62% in regular trading, trading at approximately $87.54/share, with turnover of $94.35 million.On the news front, the company's core drug candidate obefazimod faced...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174539363","title":"Movement Alert｜Abivax S.A. Overnight Decline 5.84%, Phase 3 Trial Safety Controversy Continues to Suppress Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1174539363","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174539363?lang=en_us&edition=fundamental","pubTime":"2026-06-25 15:40","pubTimestamp":1782373253,"startTime":"0","endTime":"0","summary":"On June 25, Abivax S.A. declined 5.84% overnight, trading at $87.11/share, with turnover of $339,100. The decline reflects continued market uncertainty surrounding the safety profile of the company's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144279045","title":"Movement Alert｜Abivax S.A. Falls 5.15% in Regular Trading, Phase 3 Trial Safety Controversy Stalls Recovery Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1144279045","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144279045?lang=en_us&edition=fundamental","pubTime":"2026-06-24 22:15","pubTimestamp":1782310557,"startTime":"0","endTime":"0","summary":"On June 24, Abivax S.A. declined 5.15% in regular trading, trading at $78.42/share, with turnover of $97.69 million.On the news front, the company's core drug obefazimod faced renewed selling...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029234","title":"Abivax Sa : Jefferies Raises Target Price to $108 From $90","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029234?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:08","pubTimestamp":1782126517,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42U08J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042865","title":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645042865?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:47","pubTimestamp":1782114448,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, VisteonJune 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FANG","BILL","VC","ENPH","BWIN","AMAT","CHRD","ALGM","INTC","LINT","MRK","LRCU","MTDR","FTH","CNXU","FPS","INCY","BWXT","BYD","MRNA","MRNX","AMRZ","DAR","LGN","AGMB","NBIX","ABVX","MU","LQDA","FMC","ARMK","DAL","MRNY","GLW","INTW","LRCX","AALG","KLAC","MUU","DCH","KMX","MULL","HCA","ALT","KLAG","KR","APGE","AAL","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141963401","title":"Movement Alert｜Abivax S.A. Rises 5.15% in Regular Trading, Technical Rebound Continues as Phase 3 Safety Concerns Are Digested","url":"https://stock-news.laohu8.com/highlight/detail?id=1141963401","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141963401?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:00","pubTimestamp":1781708413,"startTime":"0","endTime":"0","summary":"On June 17, Abivax S.A. rose 5.15% in regular trading, trading at $102.43/share, with turnover of approximately $58.39 million.On the news front, the stock continues its technical rebound after...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643594257","title":"Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2643594257","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643594257?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:59","pubTimestamp":1781607567,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yatin Suneja from Guggenheim reiterated a Buy rating on Abivax SA Sponsored ADR, with a price target of $175.00. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/abivax-sa-sponsored-adr-abvx-gets-a-buy-from-guggenheim-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/abivax-sa-sponsored-adr-abvx-gets-a-buy-from-guggenheim-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAVXF","BK4139","ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643532937","title":"Analysts Are Bullish on These Healthcare Stocks: Encompass Health (EHC), Abivax SA Sponsored ADR (ABVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643532937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643532937?lang=en_us&edition=fundamental","pubTime":"2026-06-16 17:52","pubTimestamp":1781603561,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Encompass Health (EHC) and Abivax SA Sponsored ADR (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-encompass-health-ehc-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-encompass-health-ehc-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGXZ23171101.USD","LU2237957811.SGD","BK4185","EHC","LU1983260115.SGD","SG9999004303.SGD","BK4139","ABVX","LU2237957902.USD","LU0054578231.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643753407","title":"Barclays Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643753407","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643753407?lang=en_us&edition=fundamental","pubTime":"2026-06-16 17:47","pubTimestamp":1781603271,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Buy rating on Abivax SA Sponsored ADR today and set a price target of $148.00. Darout covers the Healthc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAVXF","ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101619724","title":"Movement Alert｜Abivax S.A. Rises 5.03% in Regular Trading, Technical Rebound Continues as Phase 3 Safety Concerns Digested","url":"https://stock-news.laohu8.com/highlight/detail?id=1101619724","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101619724?lang=en_us&edition=fundamental","pubTime":"2026-06-16 00:26","pubTimestamp":1781540774,"startTime":"0","endTime":"0","summary":"On June 16, Abivax S.A. rose 5.03% in regular trading, trading at $102.575/share, with turnover of $79.26 million.On the news front, the stock is extending a technical rebound after its core drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163008647","title":"Movement Alert｜Abivax S.A. Falls 5.27% in Regular Trading, Phase 3 Trial Cancer Safety Concerns Compounded by Securities Fraud Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=1163008647","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163008647?lang=en_us&edition=fundamental","pubTime":"2026-06-10 23:02","pubTimestamp":1781103739,"startTime":"0","endTime":"0","summary":"On June 10, Abivax S.A. declined 5.27% in regular trading, trading at $97.595/share, with trading volume of $43.897 million. The stock continues to face dual headwinds from drug safety concerns and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117915223","title":"Movement Alert｜Abivax S.A. Falls 5.32% in Regular Trading, Phase 3 Trial Cancer Safety Concerns Continue to Weigh on Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1117915223","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117915223?lang=en_us&edition=fundamental","pubTime":"2026-06-08 22:05","pubTimestamp":1780927528,"startTime":"0","endTime":"0","summary":"On June 8, Abivax S.A. declined 5.32% in regular trading, trading at $97.13/share, with trading volume of approximately $54.04 million.The decline reflects persistent investor anxiety over safety...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641764431","title":"Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (PAHC) and Abivax SA Sponsored ADR (ABVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641764431","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641764431?lang=en_us&edition=fundamental","pubTime":"2026-06-07 22:30","pubTimestamp":1780842606,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phibro Animal Health (PAHC) and Abivax SA Sponsore...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phibro-animal-health-pahc-and-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phibro-animal-health-pahc-and-abivax-sa-sponsored-adr-abvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ABVX","XBI","XLV","HCSG","BK4581","PAHC","BK4137","LABU","BK4139","LU0128526141.USD","AAVXF","BK4585","BK4007","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169511769","title":"Movement Alert｜Abivax S.A. Falls 5.49% in Regular Trading, Phase 3 Trial Cancer Case Safety Concerns Continue to Weigh on Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1169511769","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169511769?lang=en_us&edition=fundamental","pubTime":"2026-06-05 23:19","pubTimestamp":1780672794,"startTime":"0","endTime":"0","summary":"On June 5, Abivax S.A. declined 5.49% in regular trading, trading at $99.52/share, with trading volume of $128 million. The decline reflects persistent safety concerns surrounding the company's core...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101208168","title":"Movement Alert｜Abivax S.A. Rises 5.65% in Regular Trading, Extending Rebound After Phase 3 Trial Cancer Scare Triggered 40%+ Selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=1101208168","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101208168?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:13","pubTimestamp":1780582405,"startTime":"0","endTime":"0","summary":"On June 4, Abivax S.A. rose 5.65% in regular trading, trading at $98.5/share, with trading volume of $127 million. The stock continues to rebound after plunging over 40% earlier this week.The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640718935","title":"This Is Why Abivax Stock (ABVX) Is Up Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2640718935","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640718935?lang=en_us&edition=fundamental","pubTime":"2026-06-04 02:41","pubTimestamp":1780512084,"startTime":"0","endTime":"0","summary":"Abivax stock was up after one of the company’s clinical trials was a success.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/this-is-why-abivax-stock-abvx-is-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/this-is-why-abivax-stock-abvx-is-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640850381","title":"Abivax price target lowered to $136 from $176 at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2640850381","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640850381?lang=en_us&edition=fundamental","pubTime":"2026-06-04 01:20","pubTimestamp":1780507227,"startTime":"0","endTime":"0","summary":"Wolfe Research lowered the firm’s price target on Abivax (ABVX) to $136 from $176 and keeps an Outperform rating on the shares. The firm believes t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abivax-price-target-lowered-to-136-from-176-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abivax-price-target-lowered-to-136-from-176-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abivax.com","stockEarnings":[{"period":"1week","weight":-0.0166},{"period":"1month","weight":-0.2484},{"period":"3month","weight":-0.0485},{"period":"6month","weight":-0.3149},{"period":"1year","weight":12.5794},{"period":"ytd","weight":-0.277}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.","exchange":"NASDAQ","name":"Abivax S.A.","nameEN":"Abivax S.A.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abivax S.A.(ABVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Abivax S.A.(ABVX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Abivax S.A.,ABVX,Abivax S.A.股票,Abivax S.A.股票老虎,Abivax S.A.股票老虎国际,Abivax S.A.行情,Abivax S.A.股票行情,Abivax S.A.股价,Abivax S.A.股市,Abivax S.A.股票价格,Abivax S.A.股票交易,Abivax S.A.股票购买,Abivax S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abivax S.A.(ABVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Abivax S.A.(ABVX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}